https://www.live-feeds.com/feed/seven-new-tumor-cases-reported-among-patients-on-novartis-zolgensma-gene-therapyContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/seven-new-tumor-cases-reported-among-patients-on-novartis-zolgensma-gene-therapyhttps://www.live-feeds.com/feed/seven-new-tumor-cases-reported-among-patients-on-novartis-zolgensma-gene-therapy#u186740Mon, 09 Nov 2026 00:44:30 +0000Novartis confirmed 9 reported cases of tumors in patients treated with its Zolgensma gene therapy, with 7 new cases recently reported. The gene therapy is used to treat spinal muscular atrophy (SMA). The company is investigating the potential link between the therapy and the tumors.Why it mattersZolgensma is a gene therapy treatment for spinal muscular atrophy, a genetic disorder that affects nerve cells responsible for controlling voluntary muscle movement. The treatment uses a viral vector to deliver a functional copy of the SMN1 gene to patients. The reports of tumors in patients who receiv